Xiao-I Corporation (AIXI) IPO Misrepresentation Case

• $AIXI stockholders filed a claim against Xiao-I Corporation for misleading them about its AI business, financial management, and risks tied to its Chinese shareholders.

• After a series of negative financial disclosures, $AIXI dropped by over 50% from its IPO price.

• $AIXI investors can join this case to be notified about potential recovery.

Case Details:

In March 2023, Xiao-I Corporation conducted its IPO, offering 5.7 million shares at $6.80 per share.

In July 2023, it was revealed that Xiao-I faced compliance issues with Chinese shareholders under Circular 37, which stopped the company from using IPO funds as planned.

On September 25, 2023, Xiao-I's unaudited financial results revealed that the company had overstated its AI capabilities while hiding the high R&D costs.

Additionally, In July 2024, it was revealed that Xiao-I needed to have adhered to proper accounting standards, specifically failing to comply with U.S. GAAP.

These revelations led to $AIXI plummeting by over 50%, raising concerns that the company might not meet NASDAQ’s minimum price requirements.

Based on these events, $AIXI stockholders filed a claim against Xiao-I, accusing the company of the following:

• That the company hid risks tied to Chinese shareholders’ regulatory compliance.

• That the company misled investors about its AI capabilities and financial health.

• The company downplayed the financial strain caused by high R&D costs.

Investors believe Xiao-I misled them by concealing key risks, exaggerating its AI capabilities, and understating the impact of its rising R&D expenses.